Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter P Jeske

Showing results (11-20 of 45) with videos related to

Pageof 5
Sort By:
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Factor Xa inhibitors: today and beyondJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
Current Opinion in Pulmonary Medicine|August 12, 2005
Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Methods in Molecular Medicine|January 22, 2004
Factor Xa inhibitorsJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Newer insights on the mechanism of heparin-induced thrombocytopeniaJeanine M Walenga, Walter P Jeske, M Margaret Prechel, et al.
Future Cardiology|October 7, 2009
Update on the clinical applications of argatrobanJawed Fareed, Walter P Jeske, Debra A Hoppensteadt, et al.
Journal of Thrombosis and Thrombolysis|January 12, 2012
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparinsMarc Cohen, Walter P Jeske, Jose C Nicolau, et al.
Biomarkers in Medicine|September 20, 2016
Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devicesWalter P Jeske, Jeanine M Walenga, Bryan Menapace, et al.
Expert Review of Hematology|November 19, 2010
Pharmacology of argatrobanWalter P Jeske, Jawed Fareed, Debra A Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugsJeanine M Walenga, Walter P Jeske, M Margaret Prechel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 14, 2013
Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight HeparinDebra A Hoppensteadt, Angel Gray, Walter P Jeske, et al.
Pageof 5

Showing results (11-20 of 45) with videos related to

Sort By:
Pageof 5
Current Opinion in Investigational Drugs (London, England : 2000)|May 9, 2003
Factor Xa inhibitors: today and beyondJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
Current Opinion in Pulmonary Medicine|August 12, 2005
Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopeniaJeanine M Walenga, Margaret Prechel, Walter P Jeske, et al.
Methods in Molecular Medicine|January 22, 2004
Factor Xa inhibitorsJeanine M Walenga, Walter P Jeske, Debra Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Newer insights on the mechanism of heparin-induced thrombocytopeniaJeanine M Walenga, Walter P Jeske, M Margaret Prechel, et al.
Future Cardiology|October 7, 2009
Update on the clinical applications of argatrobanJawed Fareed, Walter P Jeske, Debra A Hoppensteadt, et al.
Journal of Thrombosis and Thrombolysis|January 12, 2012
US Food and Drug Administration approval of generic versions of complex biologics: implications for the practicing physician using low molecular weight heparinsMarc Cohen, Walter P Jeske, Jose C Nicolau, et al.
Biomarkers in Medicine|September 20, 2016
Blood cell microparticles as biomarkers of hemostatic abnormalities in patients with implanted cardiac assist devicesWalter P Jeske, Jeanine M Walenga, Bryan Menapace, et al.
Expert Review of Hematology|November 19, 2010
Pharmacology of argatrobanWalter P Jeske, Jawed Fareed, Debra A Hoppensteadt, et al.
Seminars in Thrombosis and Hemostasis|April 16, 2004
Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugsJeanine M Walenga, Walter P Jeske, M Margaret Prechel, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 14, 2013
Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight HeparinDebra A Hoppensteadt, Angel Gray, Walter P Jeske, et al.
Pageof 5